Mouse Monoclonal CD85G Antibody

The CD85G antibody targets a member of the leukocyte immunoglobulin-like receptor (LILR) family, also known as ILT (immunoglobulin-like transcript) or LIR (leukocyte inhibitory receptor). CD85G (LILRG6 or ILT1) is a cell surface glycoprotein expressed primarily on myeloid cells, including monocytes, macrophages, dendritic cells, and subsets of natural killer (NK) cells. Structurally, it belongs to the activating LILR subfamily, characterized by a short cytoplasmic tail lacking inhibitory signaling motifs but associating with adaptor proteins like FcRγ to transmit activating signals. CD85G interacts with classical and non-classical MHC class I molecules, modulating immune responses by balancing inhibitory and activating signals in innate immunity. Its role spans pathogen defense, inflammation regulation, and immune tolerance. Dysregulation of CD85G has been implicated in autoimmune diseases, cancer immune evasion, and infectious disorders. Antibodies against CD85G are utilized in research to explore its functional mechanisms, including ligand-receptor interactions and downstream signaling pathways. Therapeutically, CD85G antibodies hold potential as immune checkpoint modulators—either to enhance anti-tumor responses by blocking inhibitory interactions or to suppress excessive inflammation in autoimmune conditions. Recent studies also investigate its expression patterns in tumor microenvironments, linking CD85G to immunotherapy resistance and prognosis.